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Abstract
Background: Recommendations given for intravenous iron treatment are typically not supported by a high level
of evidence. This meta-analysis addressed this by summarising the available date from clinical trials of ferric
carboxymaltose using clinical trial reports and published reports.
Methods: Clinical trial reports were supplemented by electronic literature searches comparing ferric
carboxymaltose with active comparators or placebo. Various outcomes were sought for efficacy (attainment of
normal haemoglobin (Hb), increase of Hb by a defined amount, for example), together with measures of harm,
including serious adverse events and deaths.
Results: Fourteen studies were identified with 2,348 randomised patients exposed to ferric carboxymaltose, 832 to
oral iron, 762 to placebo, and 384 to intravenous iron sucrose. Additional data were available from cohort studies.
Intravenous ferric carboxymaltose was given up to the calculated iron deficit (up to 1,000 mg in one week) for iron
deficiency anaemia secondary to chronic kidney disease, blood loss in obstetric and gynaecological conditions,
gastrointestinal disease, and other conditions like heart failure. The most common comparator was oral iron, and
trials lasted 1 to 24 weeks. Intravenous ferric carboxymaltose improved mean Hb, serum ferritin, and transferrin
saturation levels; the mean end-of-trial increase over oral iron was, for Hb 4.8 (95% confidence interval 3.3 to 6.3)
g/L, for ferritin 163 (153 to 173) μg/L, and for transferrin saturation 5.3% (3.7 to 6.8%). Ferric carboxymaltose was
significantly better than comparator in achievement of target Hb increase (number needed to treat (NNT) 6.8; 5.3
to 9.7) and target Hb NNT (5.9; 4.7 to 8.1). Serious adverse events and deaths were similar in incidence in ferric
carboxymaltose and comparators; rates of constipation, diarrhoea, and nausea or vomiting were lower than with
oral iron.
Conclusions: This review examined the available trials of intravenous ferric carboxymaltose using details from
published papers and unpublished clinical trial reports. It increases the evidence available to support
recommendations given for intravenous iron treatment, but there are limited trial data comparing different
intravenous iron preparations.
Background
Anaemia is common. A 2008 WHO report concentrat-
ing on pre-school children and women estimated that
worldwide one in four persons is affected by anaemia,
with pregnant women and preschool-age children at the
greatest risk [1]. High prevalence of anaemia is
associated with older age [2], and with acute and
chronic conditions, like chronic kidney disease [3].
Blood is expensive. In 2000/2001 the estimated UK
NHS cost for an adult transfusion was £635 for red
blood cells (RBC), £378 for fresh frozen plasma, £347
for platelets, £834 for cryoprecipitate, with large
increases over the preceding decade [4]. The cost of
providing red blood cell transfusions to surgical patients
in the USA, including major process steps, staff, con-
sumables, and direct and indirect overhead costs
amounted to between US$522 and US$1183 [5]. The
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one unit of RBC at about £130 [6], but the total annual
cost of provision and transfusion of blood products was
put at £898 millions in 2000/1, with an annual increase
of about 17% [4].
Despite differences in time and situation, it amounts
to an expensive business; it is sensible to avoid these
costs and the unnecessary use of blood where possible.
There are also potential risks, of incompatibility, infec-
tion, and iron overload in patients having recurrent
transfusions over long periods.
For iron deficiency anaemia associated with conditions
like chronic kidney disease (CKD) the first recourse is
to iron supplementation, either oral or parenteral. Anae-
mia is associated with increased morbidity, and with
increased mortality in chronic conditions [7-12], though
high Hb levels may be harmful [13,14]. Anaemia is also
associated with huge economic burden [15].
For CKD, for example, iron deficiency is a frequent
cause of anaemia, resulting from multiple blood sam-
pling, interventional procedures, gastrointestinal bleed-
ing and poor nutritional intake [3]. The severity of iron
deficiency anaemia increases with advancing chronic
kidney disease, particularly in patients on haemodialysis
[16]. The combination of CKD and a low Hb level
occurs in about 100,000 people in the UK [3]. Mainte-
nance of target range Hb levels (11-12 g/dL) in non-dia-
lysis-dependent patients with CKD is associated with
positive patient outcomes and improved quality of life
and physical function [16]. The complex interrelation-
ships between anaemia and cardiorenal function cur-
rently being teased out indicate that we have much to
learn [17].
Treatment of iron deficiency anaemia means identify-
ing and treating its cause, and replacing iron may be only
part of that [18,19]. Oral iron is neither suitable nor
effective in all patients; oral iron is poorly absorbed, and
is not well tolerated because of adverse gastrointestinal
effects [20-22]. Intravenous iron preparations were devel-
oped to overcome these problems in patients in whom
oral iron is poorly tolerated, or more rapid replacement
is required, or absorption is compromised. Intravenous
iron preparations have included iron as high or low
molecular weight iron dextran, iron gluconate, or iron
sucrose, and ferric carboxymaltose; differences include
the number of administrations required to replenish iron
stores. Some, notably iron dextrans with higher molecu-
lar weight, have been associated with hypersensitivity
reactions that have limited their use [23,24].
In some conditions, notably CKD, other factors are
important, particularly the appropriate balance between
stimulation of erythropoiesis and the provision of iron
for the manufacture of Hb [3], and the routine use of
erythropoiesis-stimulating agents (ESAs) has led to a
need for concomitant iron supplementation. Together,
ESAs and iron now form the cornerstone of anaemia
management in chronic kidney disease. Intravenous iron
supplementation is effective in CKD, with acceptable
safety; it permits replacement of iron stores for erythro-
poiesis, and improves the responsive to ESAs, as well as
reducing the requirement for costly ESA therapy and
transfusions [22,25-27].
Iron sucrose is typically administered as a slow push
injection or a 15- to 30-minute infusion in doses of 100-
200 mg, requiring multipleo u t p a t i e n tv i s i t sa n d
repeated intravenous access for patients to receive the
standard therapeutic course of 1,000 mg elemental iron.
Iron dextran can be administered as a single dose, but
this requires administration over a period of four to six
hours. In addition, iron dextran complexes can cause
fatal dextran-induced anaphylactic reactions [3,28]. Ana-
phylactic reaction is rare, with estimates for iron dextran
products of 0.6% incidence [29].
Ferric carboxymaltose (Ferinject
®) is a novel non-dex-
tran-containing complex of iron that allows for adminis-
tration of a large replenishment dose (≤1,000 mg of
iron) over a short infusion period (15-30 minutes), typi-
cally to the amount required for iron repletion. Ferric
carboxymaltose is effective in improving Hb concentra-
tions in non-dialysis-dependent patients with CKD [30].
It may be of significant benefit for use in the outpatient
department or in a community setting as a result of its
rapid and high-dose replacement of depleted iron stores
in patients with CKD, as well as in various other adult
populations with iron deficiency anaemia [30].
It has been noted that many of the recommendations
for intravenous iron treatment are not supported by a
high level of evidence [31]. This meta-analysis seeks to
address the evidence gap by summarising the available
data from clinical trials of ferric carboxymaltose using
clinical trial reports and published results. Clinical trial
reports frequently contain much more detail than is
available in published reports, if only because they are
not restricted by word count limits; meta-analyses from
clinical trial reports of other drugs have been conducted
previously [32-34].
Methods
Identification of studies
We sought randomised trials and cohort studies of the
use of intravenous ferric carboxymaltose for the treat-
ment of iron deficiency anaemia. Studies were included
if they treated iron deficiency anaemia, of any cause, for
any duration, in patients of any age, and included at
least 10 patients. Case reports or informal case series
were not eligible.
Vifor Pharma UK Limited provided PDF versions of
CTRs of phase 2/3 studies of IV ferric carboxymaltose
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®), irrespective of clinical condition or design.
Published studies were identified by searching PubMED,
using as key words Ferinject, ferric carboxymaltose, or
iron carboxymaltose in title, abstract, or anywhere in a
document. Articles identified were examined online to
assess whether they might be a clinical study of efficacy
or harm, and hard copy obtained of any regarded as
probably being randomised trials or cohort studies. In
addition, references of retrieved articles, CTRs, and
review articles [30,35,36] were examined for any other-
wise unidentified studies.
Electronic searches were conducted originally in June
2010, with additional searches at the time of submission
in February 2011. CTRs from Vifor Pharma were of
trials with completed reports up to March 2010.
Outcomes sought
We sought various different outcomes from studies. For
efficacy we sought outcomes approximating the follow-
ing:
￿ Treatment success, however defined (increase in
Hb by a defined amount, increase in Hb above a
defined level, increase in Hb plus increases in ferritin
and transferrin saturation (TSAT)).
￿ Attainment of normal Hb, however defined.
￿ Increase of Hb by a defined amount.
￿ Mean increase in Hb at various times after start of
treatment.
￿ Mean increase in serum ferritin at various times
after start of treatment.
￿ Mean increase in TSAT at various times after start
of treatment.
For measures of harm, we sought the following:
￿ Patients experiencing at least one adverse event.
￿ Patients experiencing at least one serious adverse
event.
￿ Patients dying.
￿ Patients experiencing hypertension.
￿ Patients withdrawing for any reason, because of
adverse events, or because of evidence of lack of effi-
cacy (transfusion, introduction of or change in EPO
dose, for example).
￿ Patients experiencing adverse events, as defined by
organs or body area.
￿ Patients with a specific adverse event like constipa-
tion or headache.
We also sought any information about change of hae-
matological parameters of Hb, serum ferritin, and TSAT
over time.
Analysis
Data were extracted from studies by one author, and
independently verified by another author. Any disagree-
ment was resolved by consensus, and with the aid of
another experienced researcher not connected with the
review.
Studies were assessed for quality using the Oxford
Quality Scale [37]. We defined intention to treat as a
patient being randomised and receiving at least one
dose of any treatment, and used this as the denominator
where possible.
Analyses were planned in the following way:
1. The type of comparator would determine the pri-
mary analysis (placebo, oral iron, other IV iron pre-
paration, blood). While combined analysis with
different comparators was planned, the main focus
would be with the particular comparators for
efficacy.
2. Any heterogeneity between clinical conditions
would be explored using L’Abbé plots [38], and sub-
group analyses if appropriate.
Dichotomous and continuous data were entered into
RevMan 5.0 using the appropriate statistic. For dichoto-
mous outcomes, dichotomous data were used to calcu-
late relative benefit or risk (RB, RR) with 95%
confidence intervals (CIs) using a fixed-effect model
[39]. The number needed to treat to benefit (NNT) was
calculated as the reciprocal of the absolute risk reduc-
tion [40]. For unwanted events, the NNT becomes the
number needed to treat to harm (NNH), or the number
needed to treat to prevent harm (NNTp).
For mean change over time, we planned, for each
parameter, to calculate a weighted mean by dividing the
sum of the product of mean change in concentration
and number of patients of individual studies by the sum
of the number of patients in all studies combined.
For all calculations the intention was to pool data for
analysis only when available from at least two trials and
with data available from at least 400 patients.
Results
Available studies
Electronic searches using PubMED produced 33 possible
titles; of these eight reports of randomised trials and one
report of a cohort study were included (Additional file 1;
flow diagram). Vifor provided eleven CTRs. Some pub-
lished papers duplicated CTRs, some [41-43] did not,
and some CTRs contained data that were not published.
Identification of possible duplications was achieved by
matching condition, numbers enrolled and treated, and
patient characteristics between CTRs and published
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after submission, and was included at revision, before
resubmission. Of the 11 randomised trials, five scored 5/
5 ,s e v e ns c o r e d3 / 5( b e c a u s et h e yw e r eo p e ns t u d i e s )
and one 2/5; scores of 3 or more out of 5 on this scale
are associated with a low potential for bias.
Table 1 shows the sources of information for the
available studies and the relationship between CTRs and
published studies. Information regarding efficacy or
harm was taken from sources that reported them. We
finally included 14 unique studies, 11 randomised trials
and three cohort studies:
￿ In iron deficiency anaemia secondary to kidney
disease, four studies provided data. Two were rando-
mised, open studies comparing IV ferric carboxymal-
tose with oral iron [44,45] or IV Venofer (iron
sucrose [46]). Two were cohort studies [47-49].
￿ In iron deficiency anaemia secondary to blood loss
during childbirth or associated with heavy uterine
bleeding, four randomised, open studies provided
data [41,50-55]. All compared IV ferric carboxymal-
tose with oral iron.
￿ In iron deficiency anaemia secondary to gastroin-
testinal causes, one cohort study [56] and one ran-
domised open study [57,58] provided data
comparing IV ferric carboxymaltose with oral iron.
One randomised trial compared IV ferric carboxy-
maltose with IV iron sucrose [43].
￿ Three randomised, double blind studies compared
IV ferric carboxymaltose with placebo in different
conditions. 1VIT05006 [35,59] was a one-week
crossover and CARS-1 [60] was a placebo and active
controlled study over 12 weeks in patients with iron
deficiency anaemia secondary to several different
conditions. In congestive heart failure, IV ferric
carboxymaltose was compared with placebo over 24
weeks [42].
￿ One report of a trial design in patients with iron
deficiency anaemia in the setting of non-dialysis-
dependent chronic kidney disease [61] had no results
yet available.
The 14 studies varied in duration between one and 24
weeks and involved 3933 patients, some of whom were
exposed to treatments more than once because of cross-
overs or re-randomisation into extension studies. There-
fore 2,348 patients were exposed to IV ferric
carboxymaltose in randomised trials and 348 in cohort
studies. Oral iron was administered to 832 patients, iron
sucrose to 384, and placebo to 762 in randomised trials.
Typically, IV ferric carboxymaltose was given up to the
calculated iron deficit, with no more than 1,000 mg iron
administered in a single week; thereafter smaller doses
were given on a regular basis, in, for instance, chronic
kidney disease. Details of the study designs, patients par-
ticipating, and outcomes, are given in Additional file 2
(Trial details).
Efficacy analyses - comparison with oral iron
1 Mean change in values over time
Five studies comparing IV ferric carboxymaltose with oral
iron provided data to allow a calculation of the weighted
mean change over time in Hb, serum ferritin, and TSAT
[44,50,52,54,57]. At least three studies had to provide data
for a weighted mean to be calculated at any time period;
because studies had different duration (typically up to 12
weeks for randomised studies), calculation of the weighted
mean over weeks 6-12 was done with the value available
at the longest duration. For ferric carboxymaltose, between
536 and 791 patients contributed data, and for oral iron
between 439 and 598 contributed. Estimates of statistical
Table 1 Available studies (NCT = ClinicalTrials.gov registry number)
CTR Condition NCT Published study
1VIT04004 [44] Chronic kidney disease Qunibi et al. Nephrol Dial Transplant 2010 doi: 10.1093/ndt/gfq613 [45]
1VIT04005 [47] Chronic kidney disease No publication identified
VIT-IV-CL-015 [46] Haemodialysis No publication identified
53214 [48] Haemodialysis Covic & Mircescu. Nephrol Dial Transplant 2010 25: 2722-2730 [49]
VIT-IV-CL-009 [50] Post partum anaemia Breymann et al. Int J Gynecol Obstet 2008 101: 67-73 [51]
1VIT06011 [52] Post partum anaemia Seid et al. Am J Obstet Gynecol 2008 199:435.e1-7 [53]
1VIT04002/4003 [54] Uterine bleeding NCT00395993 Van Wyck et al. Transfusion 2009 49: 2719-2728 [41]
No CTR available Post partum anaemia NCT00396292 Van Wyck et al. Obst & Gynecol 2007 110:267-278 [55]
VIT-IV-CL-03 [56] GI causes of anaemia No publication identified
VIT-IV-CL-008 [57] Inflammatory bowel disease Kulnigg et al. Am J Gastroeneterol 2008 24:1507-1523 [58]
1VIT05006 [59] Iron deficiency anaemia Bailie et al. Hemodialysis International 2010 14: 47-54 [35]
CARS 1 [60] Iron deficiency anaemia No publication identified
No CTR available Congestive heart failure NCT00520780 Anker et al. NEJM 2009 361 [42]
No CTR available CKD design NCT00981045 Szczech et al. Nephrol Dial Transplant 2010 25: 2368-2375 [61]
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from studies at different time points, and inconsistent
reporting of dispersion.
Following treatment with IV ferric carboxymaltose, the
mean Hb change from baseline increased steadily over
weeks 1 to 6, with a mean increase of about 30 g/L by
week 6 and sustained at that level to week 12 (Figure 1).
With oral iron somewhat smaller increases followed a
similar time course.
Following treatment with IV ferric carboxymaltose, the
serum ferritin change from baseline declined steadily
over weeks 1 to 6, with a mean increase of about 150
μg / Lb yw e e k6s u s t a i n e da tt h a tl e v e lt ow e e k1 2( F i g -
ure 2). With oral iron only small changes in serum ferri-
tin occurred.
Following treatment with IV ferric carboxymaltose, the
mean TSAT increased steadily from baseline to week 4
and then declined slightly; the mean increase was about
22% by week 6 and remained at that level at that level
to week 12 (Figure 3). With oral iron somewhat smaller
increases were seen.
2 Hb Responders
Response was defined in various ways: by achieving a tar-
get Hb increase (typically ≥20 g/L increase), by achieving a
target Hb level (typically ≥120 g/L), or by achieving what
was typically described as clinical success in the original
reports (typically a rise in Hb of ≥20 g/L plus ferritin
increase of ≥150 μg/L or TSAT increase of ≥20%). Some
studies used several of these definitions. Table 2 shows the
results of analyses for responders, for all comparators, and
for oral iron only. There was good consistency between
trial results for all three definitions of responder, with stu-
dies demonstrating considerable homogeneity, as the
L’Abbé plots in Figures 4, 5, and 6 show.
With IV ferric carboxymaltose 70-80% of patients
achieved target Hb increases or target Hb levels,
somewhat more than with controls, and producing
NNTs of about 6 compared with oral iron. For clinical
success similar high levels of response were found for
IV ferric carboxymaltose, but the failure of oral iron in
particular to increase ferritin levels resulted in low rates
of clinical success, with consequent high relative benefit,
and low (good) NNTs of about 1.5. The time course of
r e s p o n s e( F i g u r e7 )s h o w e dt h a tm a x i m u mr e s p o n s e
rates were typically achieved by 4-6 weeks.
3 Serum ferritin and TSAT responders
Responder definitions were also used for serum ferritin
and TSAT in three studies [46,50,57]. For ferritin the
definition was for serum ferritin at four weeks to be
between a minimum of 50, 100, or 200 μg/L and a max-
imum of 800 μg/L. This was achieved by about 60%
after IV ferric carboxymaltose, but lower numbers of
controls. In comparison with oral iron, the NNT to
achieve target ferritin at four weeks was about 3 (Table
3). For TSAT, about 65% achieved target values of being
1 2 4 6 6-12
0
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Mean Hb change (g/L)
Weeks from start of treatment
Ferric carboxymaltose
Oral iron
Figure 1 Time course for Hb changes.
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Mean ferritin change (µg/L)
Weeks after start of treatment
Ferric carboxymaltose
Oral iron
Figure 2 Time course for serum ferritin changes.
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Mean TSAT change (%)
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Oral iron
Figure 3 Time course for TSAT changes.
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boxymaltose, about the same as with control (Table 3).
4 Mean changes
Studies also reported mean changes in Hb, serum ferri-
tin, and TSAT over the duration of the study. Figure 8
shows the difference between IV ferric carboxymaltose
and oral iron in five trials reporting data. For Hb, the
mean improvement over oral iron was 4.8 (95%CI 3.3 to
6.3) g/L. For serum ferritin, the mean improvement was
163 (95%CI 153 to 173) μg/L. For TSAT, the mean
improvement was 5.3 (95%CI 3.7 to 6.8)%. All were sta-
tistically significant improvements over oral iron.
Efficacy analyses - active comparisons and cohort studies
One randomised double blind placebo controlled trial
provided information on efficacy of IV ferric carboxy-
maltose in anaemia associated with heart failure.
Another randomised open study compared IV ferric car-
boxymaltose with IV iron sucrose. Three cohort studies
also provided additional information on the use of ferric
carboxymaltose.
Active comparisons
A randomised double blind trial of IV ferric carboxy-
maltose for treating heart failure randomised 459
patients to IV ferric carboxymaltose or IV placebo, and
reported results at 24 weeks, according to initial Hb
level [42]. Half the patients had Hb levels ≤120 g/L initi-
ally, and for these mean final Hb was higher (127 g/L)
after IV ferric carboxymaltose than IV placebo (118 g/
L). Final levels of ferritin (275 vs 68 μg/L) and TSAT
(29% vs 17%) were also higher after IV ferric carboxy-
maltose than placebo.
A randomised open trial compared IV ferric carboxy-
maltose with IV iron sucrose for treating iron deficiency
Table 2 Hb responder analysis
Number of Percent with
Outcome Comparator Trials Patients Ferric
carboxymaltose
Control RB
95% CI
NNT
95% CI
Target Hb increase All 6 1715 78 63 1.2 (1.2 to 1.3) 6.8 (5.3 to 9.7)
Oral iron 5 1481 74 59 1.3 (1.2 to 1.4) 6.6 (5.0 to 9.6)
Achieve target Hb level Oral iron 5 1509 79 62 1.3 (1.2 to 1.4) 5.9 (4.7 to 8.1)
Clinical success All 4 1167 70 2 37 (20 to 67) 1.5 (1.4 to 1.6)
Oral iron 3 984 78 0 250 (51 to 1190) 1.3 (1.2 to 1.3)
0
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Target Hb increase with ferric carboxymaltose (%) 
Target Hb increase (%) with control
0
500
1000
Figure 4 L’Abbé plots for percentage of patients achieving a
target Hb increase (yellow with oral iron comparator, red for
intravenous iron sucrose (Venofer)). Each symbol represents one
trial, with size of symbol proportional to number of patients
randomised using the inset scale.
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Figure 5 L’Abbé plots for percentage of patients achieving a
target Hb (yellow with oral iron comparator). Each symbol
represents one trial, with size of symbol proportional to number of
patients randomised using the inset scale.
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(ulcerative colitis and Crohn’s disease) in 475 patients
[43]. Patients had initial Hb levels below 120 g/L in
women or 130 g/L in men. The primary outcome of
increase in Hb by at least 20 g/L was achieved by 66%
with ferric carboxymaltose and 54% with iron sucrose.
Achievement of a normal Hb occurred in 73% with fer-
ric carboxymaltose and 62% for iron sucrose; normal
TSAT (20-50%) was achieved in 53% and 36%, and nor-
mal ferritin (≥100 μg/L) by 43% and 27% respectively.
T h et i m ec o u r s ef o rt h e s ec h a n g e sw a ss i m i l a rt ot h a t
seen in the oral iron comparisons.
This study also compared cost effectiveness of the two
regimens. Although ferric carboxymaltose has a higher
cost per treatment than iron sucrose (US$ 311 vs 154),
the greater number of infusions with iron sucrose
resulted in a higher overall treatment cost (US$ 653 for
ferric carboxymaltose and US$ 891 for iron sucrose).
Treatment with iron sucrose thus costs US$ 238 more
than ferric carboxymaltose, but with a 12% lower chance
of hitting the target increase in Hb.
Cohort studies
In a non-randomised extension study in patients with
kidney disease [47] where treatment duration (up to 43
weeks) depended on the degree of anaemia, IV ferric
carboxymaltose resulted in a mean Hb increase of 19 g/
L and clinical success (Hb ≥100 g/L, ferritin 100-800
μg/L, TSAT 30-50%) of 72/140 (51%). Most patients
had serum ferritin in the range 100-800 μg/L (99%), and
TSAT 30-50% (76%).
An open cohort study in patients receiving haemodia-
lysis lasting 10 weeks, with 200 mg IV ferric carboxy-
maltose two or three times a week during haemodialysis
sessions [48] produced a mean increase in Hb of 10 g/L,
with 73% and 82% of patients with more than 10 g/L at
2 and 4 weeks. The mean ferritin increase was 403 μg/L,
and TSAT increase 16%.
In anaemia secondary to a gastrointestinal disorder, 46
patients were given either 500 mg IV ferric carboxymal-
tose weekly for four weeks or 1000 mg weekly for two
weeks [56]. Most patients had increases in Hb of ≥20 g/
L, with 34/46 (74%) having normal Hb (≥140 g/L for
men and ≥120 g/L for women). The mean Hb increase
was above 20 g/L.
Withdrawals and adverse events - comparison with oral
iron
1 Withdrawal
All cause withdrawals, in all randomised studies combined,
were slightly less frequent with IV ferric carboxymaltose
than with controls (oral iron, IV iron, and IV placebo;
Table 4), though only by about 1% (NNT to prevent one
withdrawal 93). There was no significant difference in the
comparison with oral iron, nor was there any significant
difference between IV ferric carboxymaltose and any con-
trol for adverse event or lack of efficacy withdrawal.
2 Adverse events
No significant difference was found between IV ferric
carboxymaltose for patients experiencing at least one
adverse event, death, and any serious adverse event. For
hypotension, IV ferric carboxymaltose produced signifi-
cantly more events than oral iron, with a NNH of 79
(Table 4). Hypotension associated with IV ferric carbox-
ymaltose was not a factor in any deaths.
0
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Clinical success (%) with control
0
500
1000
Figure 6 L’Abbé plots for percentage of patients achieving
clinical success, however defined (yellow with oral iron
comparator, red for intravenous iron sucrose (Venofer)). Each
symbol represents one trial, with size of symbol proportional to
number of patients randomised using the inset scale.
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Figure 7 Time course of Hb responders.
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Adverse events were reported according to body sys-
tems, and Table 5 shows analyses for IV ferric carboxy-
maltose compared with oral iron and with IV placebo.
In the comparison with oral iron, IV ferric carboxymal-
tose produced fewer gastrointestinal events (13% com-
pared with 32%, NNTp 5), but more general and
administrative site events (NNH 15) and abnormalities
in metabolism, nutrition, and investigations (NNH 17).
Compared with IV placebo, IV ferric carboxymaltose
produced more gastrointestinal and general and admin-
istrative site events (NNH 34 and 25, respectively).
4 Specific adverse events
Table 5 also shows specific adverse events mentioned in at
least three comparisons between IV ferric carboxymaltose
and oral iron. IV ferric carboxymaltose produced less con-
stipation (3% vs 13%, NNTp 10), nausea and vomiting (3%
vs 10%, NNTp 14), and diarrhoea (2% vs 5%, NNTp 33).
Table 3 Serum ferritin and TSAT responder analysis
Number of Percent with
Outcome Comparator Trials Patients Ferric
carboxymaltose
Control RB
95% CI
NNT
95% CI
Target ferritin increase All 3 611 61 43 1.6 (1.3 to 1.9) 5.6 (3.9 to 10)
Oral iron 2 428 59 22 2.7 (2.0 to 3.6) 2.7 (2.2 to 3.6)
Target TSAT increase All 3 611 65 62 1.1 (0.9 to 1.2) not calculated
Oral iron 2 428 64 59 1.1 (0.9 to 1.3) not calculated
Figure 8 Mean improvements with intravenous ferric carboxymaltose and oral iron, for Hb (8a), ferritin (8b), and TSAT (8c).
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In the randomised comparison of IV ferric carboxymal-
tose with IV placebo in patients with heart failure [42],
all cause withdrawal occurred in 9% of patients on ferric
carboxymaltose and 13% with placebo. Deaths occurred
less frequently with ferric carboxymaltose (5/304, 1.6%)
than with placebo (4/155, 2.6%). The randomised com-
parison of IV ferric carboxymaltose with IV ferric
sucrose in inflammatory bowel disease [43] led to few
all cause withdrawals (9% vs 11%), and few patients
reported any adverse event (14% vs 11%). One serious
adverse event was reported with ferric carboxymaltose,
Table 4 Withdrawals and adverse events
Number of Percent with
Outcome Comparator Trials Patients Ferric
carboxymaltose
Control RB or RR
95% CI
NNTp
95% CI
Withdrawals
All cause All 10 3835 6.4 7.5 0.8 (0.6 to 0.9) 93 (37 to 180)
Oral iron 6 1898 8.1 9.3 0.8 (0.6 to 1.03) not calculated
Adverse event All 8 3319 1.0 1.6 0.6 (0.3 to 1.02) not calculated
Oral iron 6 1898 1.5 1.9 0.7 (0.3 to 1.4) not calculated
Lack of efficacy All 7 2967 0.6 0.8 0.8 (0.4 to 1.7) not calculated
Oral iron 5 1546 1.1 1.2 0.8 (0.4 to 1.9) not calculated
Adverse events NNH
95% CI
At least 1 AE All 8 2951 41 38 1.1 (1.0 to 1.2) not calculated
Oral iron 5 1539 48 53 1.0 (0.9 to 1.1) not calculated
Death All 10 3762 0.53 0.3 1.3 (0.5 to 3.4) not calculated
Oral iron 6 1891 0.38 0.0 1.7 (0.4 to 6.6) not calculated
Serious AE All 8 3303 2.5 2.3 1.0 (0.6 to 1.5) not calculated
Oral iron 6 1891 3.1 2.3 1.3 (0.7 to 2.2) not calculated
Hypotension All 6 2694 1.5 1.0 1.5 (0.8 to 2.7) not calculated
Oral iron 4 1339 1.3 0.0 4.7 (1.1 to 21) 79 (44 to 390)
Table 5 Adverse events by body system and specific adverse events
Number of Percent with
Outcome Trials Patients Ferric
carboxymaltose
Control RB or RR
95% CI
NNTp/H
95% CI
Comparison with oral iron
Body system and preferred term
GI disorder 5 1539 13 32 0.44 (0.36 to 0.54) 5.4 (4.4 to 7.1)
General, administrative site 5 1539 11 4 2.8 (1.9 to 4.2) 15 (11 to 24)
Infection, infestation 5 1539 14 12 1.2 (0.9 to 1.6) not calculated
Metabolism, nutrition, investigation 4 1195 11 5 2.2 (1.4 to 3.4) 17 (11 to 33)
Nervous system 5 1539 10 9 1.3 (0.9 to 1.7) not calculated
Specific adverse events
Constipation 4 1339 3 13 0.3 (0.2 to 0.4) 9.8 (7.6 to 14)
Diarrhoea 3 906 2 5 0.5 (0.2 to 0.9) 33 (18 to 230)
Nausea/vomiting 3 906 3 10 0.4 (0.2 to 0.6) 14 (9.5 to 27)
Headache 5 1539 7 7 1.2 (0.8 to 1.7) not calculated
Comparison with IV saline
Body system and preferred term
GI disorder 2 1577 8 5 1.6 (1.1 to 2.4) 34 (19 to 210)
General, administrative site 2 1577 6 2 2.5 (1.5 to 4.3) 25 (17 to 49)
Infection, infestation 2 1577 9 6 1.1 (0.8 to 1.6) not calculated
Nervous system 2 1577 8 6 1.2 (0.9 to 1.8) not calculated
Respiratory system 2 1577 2 2 0.8 (0.4 to 1.5) not calculated
Note NNTp in normal text, NNH when bold
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years).
In the three cohort studies [47,48,56] 345 patients
were treated with IV ferric carboxymaltose. Of these 75
( 2 1 % )w i t h d r e wf o ra n yr e a s o n ,a n d1 4( 4 % )b e c a u s eo f
adverse events. At least one adverse event was experi-
enced by 197 (56%), serious adverse events by 35 (10%),
and hypotension by 10 (3%).
Death - all studies
There were 20 deaths. These occurred in 15 patients
treated with ferric carboxymaltose because of unstated
cardiovascular causes (4), myocardial infarction after
withdrawal, cardiac arrest, peripartum cardiomyopathy,
acute heart failure, prostate cancer, trauma, perforation
following diverticulitis, gastrointestinal bleeding follow-
ing laparoscopy, pulmonary tuberculosis, infection with
Aeromonas pulmoniae, and one unknown cause. With
iron sucrose there was one death from cardiac failure,
and for placebo there were four deaths with unstated
cardiovascular causes. Crude mortality rates were 0.6%
(15/2696) with IV ferric carboxymaltose, 0.3% (1/382)
with IV iron sucrose, 0.5% (4/762) with placebo, and 0%
(0/832) with oral iron.
Discussion
Our knowledge of iron metabolism is still in a state of
rapid development [62-64], but however involved it may
turn out, we have to interpret the evidence from com-
pleted studies on the basis of the tests used at the time. In
the case of the ferric carboxymaltose studies, this meant
mainly Hb, serum ferritin, and TSAT. Complications arise
when assessing the evidence on anaemia in different con-
ditions and with different causes (chronic kidney disease,
uterine or postpartum bleeding, gastrointestinal disease,
heart failure), using different comparators (oral iron, IV
iron, placebo), and from patients receiving erythropoietin.
Moreover, haematological outcomes are reported in differ-
ent ways, typically average change in value, or response or
nonresponse, but with differing definitions of response.
Trials also had different regimens for giving IV iron,
mainly because of different clinical requirements.
Unfortunately some randomised studies were not
blind, and others were non-comparative, which does
weaken the strength of the evidence available. Set
against this were the relatively large numbers of patients
reported on, often concerning appropriate duration, and
the consistency of response not only between different
trials for similar outcomes, but also between randomised
and non-comparative studies. A further strength was the
availability of CTRs as well as published articles for a
number of trials. CTRs are much more detailed than
published reports because they are not constrained by
word limits, or limits on tables and figures. Most CTRs,
for example, comprised over 100 pages, and at least one
over 1,000 pages of details. CTRs have been used for a
number of meta-analyses where more insightful exami-
nation of clinical trials has been needed. They have been
used, for example, in reporting adverse events [33], and
determining different outcomes in erectile dysfunction
[32] and pain [65].
Comparing IV ferric carboxymaltose with oral iron
showed a similar time course for Hb and TSAT, though
at each time point results for oral iron were numerically
worse. Oral iron had no effect on ferritin. Where
response was defined as achievement of target Hb, pre-
set Hb rise, or preset Hb rise together with preset
changes in ferritin and/or TSAT, there was a statistically
significantly better result for ferric carboxymaltose, with
NNTs in the range of 6-7, but as low as 1.5 when clini-
cal success was defined with ferritin changes. The much
lower, better, NNT reflected the lack of any effect of
oral iron on serum ferritin. However response was
defined, the response rate with ferric carboxymaltose
was in the range of 70-80% (Table 2).
Ferric carboxymaltose produced significantly greater
improvements in mean Hb, ferritin, and TSAT in the
five trials that compared them, with an average improve-
ment of about 5 g/L, 163 μg/L, and 5% respectively (Fig-
ure 6). These figures were obtained at the end of the
trials when the increase in ferritin seen soon after ther-
apy started had declined (Figure 2).
In general, and with large numbers of patients, there
was little difference in terms of withdrawals and adverse
events, including serious adverse events or hypotension,
between ferric carboxymaltose and all comparators or
oral iron alone.
There were more deaths in the trial arms using ferric
carboxymaltose than with control; they were no more
frequent than with placebo or iron sucrose, at between
0.3% and 0.6%, though none occurred with oral iron. In
the largest and longest study compared with placebo,
death rates were similar in the two groups, and 5 of the
11 deaths with ferric carboxymaltose occurred in that
trial [42]. Recent reanalyses of trials of ESAs points to
rapid Hb increases as being associated with higher mor-
tality risk [66]. If that finding were replicated with IV
iron, with or without use of ESA, it might point to a
mechanism where too rapid restoration of iron stores
was also associated with an increased mortality risk. The
emerging view is that serious adverse events have
declined with newer IV iron preparations, such that
benefits outweigh any risks [67].
In terms of specific adverse events, ferric carboxymal-
tose was associated with lower rates of constipation,
diarrhoea and nausea or vomiting than oral iron, but
injection site reactions were higher compared to other
parenteral iron preparations.
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was not able to assess. For example, no studies com-
pared ferric carboxymaltose with blood transfusion, and
direct comparisons between different IV iron products
were limited in number, but clearly of interest. This lim-
ited the comparison mainly to that between IV ferric
carboxymaltose and oral iron. The rate of decline in Hb
after stopping treatment with ferric carboxymaltose or
oral iron would have been of interest, particularly in
some patient groups. This review goes some way to
improving the level of evidence available to support
recommendations given for IV iron treatment [38], but
is not yet a complete response because of the lack of
clinical trials. The review was also limited in being able
to obtain useful health economic data except from one
r e c e n tt r i a l[ 4 3 ]t h a td e m o n s t r a t e dal o w e rc o s tf o rI V
ferric carboxymaltose over IV iron sucrose, but with a
higher success rate. Recent analyses also show that not
treating anaemia in CKD with IV iron or ESAs led to
greater mortality and cost [68].
Conclusions
There is substantial evidence that IV ferric carboxymal-
tose is effective in treating iron deficiency anaemia in
many chronic conditions. The review increases the evi-
dence available to support recommendations given for
IV iron treatment, but there are limited trial data com-
paring different IV iron preparations.
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